Treatment options for XLH are currently expanding beyond phosphate and vitamin D. A novel treatment with burosumab, a FGF-23 antibody, has shown superiority to conventional treatments regarding improvement of rickets and linear growth (38). The gene discussed is FGF23; the disease is rickets.